Sangamo BioSciences buys Ceregene

Sangamo BioSciences (SGMO) will acquire privately held Ceregene which specializes in AAV gene therapies.

The deal gives SGMO CERE-110, a Phase 2 investigational Alzheimer's drug that contains the gene for nerve growth factor. Results are expected in 2015. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs